These aren’t the RFPs you’re looking for

Oklahoma recently became the fourth US state to file a lawsuit against opioid manufacturers, and they won’t be the last. States like Delaware have even begun asking for RFPs from private law firms. The uptick in lawsuits against opioid producers has many drawing comparisons to lawsuits against Big Tobacco in the 90s. Those ended up costing the involved companies over $200 billion. If there’s something similar coming down the road for “Big Pharma” (which is not only a conspiracy theory, but also apparently a game?) then it won’t be a mere drop in the bucket. The entire pharma industry made $778 billion in prescription sales last year, so a similar fine against a small group of companies could leave them hurting.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Oral anticoagulants…who needs ‘em?

Patients with atrial fibrillation do! According to a new study, hundreds of thousands of patients aren’t receiving them each year. Folks with AFib are at a very high risk for stroke, and guess what? Oral anticoagulants—a.k.a. blood thinners—can reduce the risk by two-thirds and direct oral anticoagulants (DOACs) are proven to be just as effective, if not more so. No, this isn’t a groundbreaking new therapy. Quite the opposite. DOACs have been available since 2010. 655,000 patients were evaluated in the study and the data show that over a seven-year period, only 6 out of 10 patients with high stroke risk were prescribed these potentially life-saving meds. This guy sums it up best.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

The road to America’s opioid epidemic is paved with good intentions

A study published in Pediatrics last week demonstrated that many teens who abuse opioids start out being prescribed them for legitimate medical use. The bad side of that is pretty obvious, but there’s a good side to this revelation as well—knowing that physicians are integral to an important piece of this problem means that we can go about designing effective solutions for it. Like those “careful prescribing practices” we keep hearing about. Some more good news, this study and another published last week both report a decline in opioid misuse among youth. Keep fighting the good fight docs, and one day we’ll celebrate that the kids are alright.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

2. The war on drug stores heats up

Recent power plays in the prescription drug industry make J.R. Ewing’s actions seem like child’s play. If you don’t track the specialty pharmacy market, you should. This is a $100B industry that is growing rapidly. Think high-priced drugs used to treat Hep C and Cystic Fibrosis. According to the New York Times, large PBMs might be trying to force out independent specialty pharmacies. In Alabama, BCBS recently told patients that they cannot have their prescriptions filled at CVS. This is a big deal. It means patients have to sever long-standing relationships with pharmacists, especially difficult with specialty indications. This is all part of an emerging trend to narrow networks. Look it up. You will be glad you did and you’ll be smarter.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn